Articles tagged with Cancer Medication
Researchers found that immunosuppressive therapy does not increase the occurrence or recurrence of vulvar or vaginal cancer in women with IBD, but an earlier onset was reported. Lymphomas were also found in some patients, which is rare in the genital tract.
A doctors' group is suing California for neglecting to add processed meat, such as hot dogs and bacon, to the state's cancer-causing substances list under Proposition 65. This move comes after experts classified consumption of processed meat as carcinogenic to humans, increasing risks of colorectal, breast, prostate, pancreatic, and ov...
Researchers at Boston Children's Hospital have discovered a new approach to cancer immunotherapy by reactivating the gasdermin E gene, which can convert 'cold' tumors into 'hot' ones that the immune system can target. The team showed that re-introducing gasdermin E in mouse models triggered pyroptosis and suppressed tumor growth in var...
Researchers found a toxic fungus previously thought to not be infectious in the sinus tissues of a man with refractory acute lymphocytic leukemia. The team successfully treated the infection using available antifungal drugs.
Researchers developed a substance that targets cancer cells with defective NAT2 gene, potentially treating colorectal cancer patients worldwide
Researchers at UC have discovered a mechanism that could lead to new immunotherapies for patients with head and neck cancers. By understanding how calmodulin interacts with ion channels in immune cells, scientists may be able to develop new treatments to restore the ability of these cells to enter and kill tumors.
Researchers have identified a new target in 'normal cells' for a potential treatment of triple negative breast cancer. Using PIK3Cδ inhibitors, the study found a reduction in tumour growth and improved survival outcomes when levels of the protein were controlled in surrounding healthy tissue.
The National Comprehensive Cancer Network (NCCN) has published a list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts and include endorsement of 15 existing measures and seven new concepts proposed for development.
The Annual Review of Cancer Biology has converted to open access, making its content freely available worldwide. The move is part of a pilot program called Subscribe to Open, which uses existing library relationships and subscription purchases to convert gated journals to open access.
Researchers have identified a promising new drug combination that can help the immune system target and kill cancer cells. By combining an anti-nausea drug with existing cancer treatments, the treatment works by altering the surface of tumor cells to make them more recognizable to the immune system.
Researchers discovered a new function of neurofibromatin, directly repressing estrogen receptor-alpha expression and causing treatment resistance in ER+ breast cancer. A combination therapy of SERD and MEK inhibitor was shown to be effective in animal models and is being tested in clinical trials.
Scientists have developed a free computer program called HemoSYS to quantify structural and functional changes in tumor blood flow networks. The tool provides insights into cancer progression and metastasis, potentially accelerating the development of new therapies targeting tumor blood vessels.
The City of Hope's innovative platform enables researchers to access and analyze the data from the California Teachers Study, a 25-year study on cancer, heart conditions, and Alzheimer's disease. This move aims to fast-track scientific discoveries and improve quality of life for people worldwide.
A pilot study at USC found that an MAO inhibitor called phenelzine can help patients with recurrent prostate cancer by disrupting tumor growth pathways. The drug has fewer side effects compared to standard hormone therapy treatments.
A new experimental platform for cancer diagnostics, prognoses, and testing cancer drugs has been developed by analyzing the extracellular matrix of tumor tissues. The platform uses protein fibers surrounding cells to predict disease risk and potential treatment efficacy in various patients with different types of cancers.
Researchers at NYU Abu Dhabi have designed nanocarriers to effectively deliver chemotherapeutics specifically to cancer cells, while minimizing exposure of healthy tissue. The nanoparticles demonstrate potent anticancer activity with a substantial reduction in tumor volume and mass.
Researchers found that inhibiting IDO1 protein helps radiation destroy tumor cells while preserving healthy tissue. Combining radiation with the inhibitor increased cell death within tumors and improved protection of healthy tissue.
Researchers at University of California, Irvine discovered that cancer cells use a process called macropinocytosis to obtain nutrients from dead cell material within tumors. This mechanism enables tumor cells to resist chemotherapy and other treatments, making it a promising target for new therapies.
A study led by the University of Southampton found that a new drug, GKT137831, can break down the barrier preventing lymphocytes from attacking cancer cells. This approach may significantly improve the success rate of cancer immunotherapy treatment for many patients.
Yong Lu and David Soto-Pantoja receive grants to study immunotherapy and cardiotoxicity, aiming to improve cancer treatment outcomes and prevent heart disease. Their research could lead to new approaches in combating metastatic and treatment-resistant cancers.
New research on cancer cells' interaction with their environment reveals the importance of physical cues in guiding cell migration. A novel optical tweezer-based tool probes mechanical cues to study tumor behavior.
Researchers at Ohio State University developed RNA nanoparticles to deliver chemotherapeutic drugs paclitaxel and camptothecin, increasing their water solubility and targeting tumor cells. The nanoparticles showed precise drug loading and retention of anti-tumor activity with minimal toxicity.
A clinical trial has found that a combination of ipilimumab and nivolumab immunotherapies can shrink tumors in 44% of patients with high-grade neuroendocrine cancer. The trial, DART, offers new hope for rare cancer treatment, which accounts for almost a quarter of all cancers diagnosed worldwide.
Researchers have identified two leukemia drugs that could be used to treat lung cancer patients with triple mutant EGFR, a type of non-small cell lung cancer. The drugs, gilteritinib and midostaurin, were found using a new live cell-based method developed by the University of Toronto team.
Researchers have identified a novel mechanism for repairing genetic mistakes, which involve cross-talk between enzymes that read and correct DNA recipes. This discovery has significant implications for our understanding of cellular processes and the development of treatments for diseases such as cancer.
Researchers at Sanford Burnham Prebys Medical Discovery Institute and Harvard University discovered that mitochondria trigger senescence in cells by communicating with the cell's nucleus. They identified an FDA-approved drug that helped suppress the damaging effects of senescence in cells and mice, providing a potential treatment for a...
A new study reveals that MNT is required for the survival of MYC-driven lymphoma cells, suggesting a promising new approach for treating this type of cancer. Inhibiting MNT may also make tumours more susceptible to other drugs, offering hope for improved treatments.
Researchers at USC Viterbi School of Engineering designed a new drug combination that mimics glucose deprivation in cancer cells, leading to their death. The combination may have fewer side effects than traditional chemotherapies and reduce the incidence of acquired resistance.
A clinical trial has identified HIF-2α as a pivotal protein in the progression of clear cell renal cell carcinomas, which is susceptible to inhibition by PT2385. The study found that the drug effectively blocks cancer-promoting genes and starves tumors of blood.
Researchers are working on developing drugs that inhibit the function of NLRP3, an inflammatory protein involved in various diseases such as atherosclerosis, cancer, Alzheimer's, Parkinson's, and arthritis. Several NLRP3 inhibitors are currently in preclinical trials with varying mechanisms.
A randomized, double-blind trial compared the safety and efficacy of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma. F14512 demonstrated significant antitumor activity and clinical benefits, particularly in P-glycoprotein overexpressing lymphomas.
Researchers developed a smart material that can analyze multiple environment parameters to ensure effective drug delivery. The material achieves high sensitivity in detecting low concentrations of DNA, making it promising for express DNA analysis and next-generation drugs.
Researchers at Johns Hopkins Kimmel Cancer Center found that combining TAK228 and trametinib may be more effective than either drug alone in decreasing pediatric low-grade glioma growth. The combination therapy also suppressed activity in key cell signaling pathways, reducing tumor growth and increasing survival in mice.
Researchers found elevated risks of skin cancer, gastrointestinal and blood side effects, as well as liver test abnormalities and cirrhosis in participants taking low-dose methotrexate. The study provides a detailed side-effect profile that may inform more informed prescribing practices.
Researchers discovered that hyper-activation of Notch and Wnt signalling is connected to dysregulation of PRH protein, which controls genes and signaling pathways. By tailoring medication according to individual PRH expression levels, clinical efficacy may be improved for patients with bile duct cancer.
A new study provides an unprecedented look at the molecular steps of endometrial cancer, offering insights into tumor aggressiveness and patient responses to treatment. The research also suggests potential new roles for already-approved drugs targeting proteins like CDK12, SMARCA4, and PML in other types of cancer.
Researchers at City of Hope have discovered a link between the circadian rhythm gene BMAL1 and the suppression of tumor growth in obese and prediabetic mice. The study found that mice without the BMAL1 protein experienced accelerated breast tumor growth, suggesting that increasing BMAL1 levels may slow cancer progression.
Researchers at The Ohio State University Comprehensive Cancer Center argue that graphic warning labels can effectively promote an understanding of the consequences of smoking. The proposed labels, which include images and text warnings, have the potential to help reduce smoking rates and serve as a model for other regulatory efforts.
Researchers have designed new quinazolinone derivatives that effectively kill brain-eating amoebae, including Naegleria fowleri and Balamuthia mandrillaris. The compounds' low toxicity for human cells makes them promising candidates for drug development.
Researchers have designed a novel probiotic strain that can seek out solid tumors and safely deliver immune checkpoint inhibitors, leading to tumor regression. The probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling effective therapeutic combinations for difficult-to-treat cancers.
Researchers at KAIST have discovered mechanisms that fuel a 'domino effect' in cancer drug resistance, enabling failed responses to paclitaxel to speed up the evolution of resistance to other drugs. The study suggests a new strategy for improving second-line cancer treatment.
Professor Lillian Siu receives TAT 2020 Honorary Award for her contributions to early drug development and phase I trials in head and neck malignancies. She advances the field of cancer drug development with innovative clinical trial designs and methodologies.
A type of micro RNA known as MIR1249 plays a key role in allowing bile duct cancers to resist chemotherapy. The researchers hope that targeting this molecule could make chemotherapy more effective.
Scientists have identified a peptide from the foot-and-mouth-disease virus that targets a protein on pancreatic cancer cells, allowing for highly potent drug delivery and complete tumour killing in mice. The research offers a promising new approach to treating pancreatic cancer with limited side effects.
A phase 2 randomized trial study found that patients who received the Triplex vaccine had 50% fewer CMV complications and developed immunity against the virus. The vaccine showed promise as a potential therapy for transplant recipients with weakened immune systems.
Research found that statins, alone or with metformin, increase survival in men with high-risk prostate cancer. Metformin plus statin was associated with a 36% reduction in risk of death compared to non-users, while statins alone showed a 54% reduction in PCA mortality among patients with high-risk prostate cancer.
Researchers discovered that combining alectinib with EGFR-inhibitors prevents CNS metastasis progression in mouse model. This combination treatment overcomes alectinib resistance, offering potential novel therapies for NSCLC and secondary cancers.
A new study creates personalized cancer vaccines that amplify the effects of immunotherapy, curing mice with treatment-resistant tumors. Researchers used a molecule called APOBEC3B to drive rapid genetic changes in cancer cells, creating unique signatures vulnerable to immune checkpoint blockade.
A study published in Addiction found that providing smokers with free, two-week nicotine replacement therapy (NRT) starter kits increased quit attempts and smoking abstinence. The intervention also showed promise for low-income patients, those with lower education levels, and rural residents.
Researchers have cataloged genetic fingerprints of DNA-damaging processes that drive cancer development, providing clues to how each cancer develops. This list allows scientists to search for previously unknown chemicals and biological pathways responsible for causing cancer.
A University of New Mexico Health Sciences Center-led research team has discovered a cancer-fighting compound that also reduces fat in obese mice. The team found that the compound, G-1, increases energy expenditure and targets brown fat cells, leading to weight loss and improved diabetes symptoms.
APG-157, a plant-based drug containing curcumin, was shown to reduce inflammation and attract immune cells to tumor tissues in patients with oral and oropharyngeal cancers. The treatment also decreased Bacteroides species and had no adverse effects.
A study of 125,500 Danish patients with atrial fibrillation found that those who experienced bleeding were between 11 and 24 times more likely to be diagnosed with bowel cancer. Patients who had gastrointestinal bleeding should always be offered meticulous clinical examination regardless of anticoagulant treatment.
A recent study cataloged genetic fingerprints of DNA-damaging processes driving cancer development, providing clues on how each cancer developed. The research will help understand cancer causes, inform prevention strategies, and signpost new directions for diagnosis and treatments.
A study of 140 older patients with non-metastatic cancer found that those with negative attitudes toward aging were more likely to die prematurely. Participants with a positive self-perception of aging had a significantly lower risk of death compared to their negative counterparts.
The Pan-Cancer Project has created the most comprehensive map of cancer genomes to date, improving our understanding of cancer and its diagnosis. Researchers have identified key regions controlling gene expression and discovered a 'carbon dating' method to pinpoint mutations in tumors years before they appear.
The Damon Runyon Cancer Research Foundation has awarded $231,000 in funding to 16 postdoctoral scientists conducting innovative cancer research projects. The Fellowship aims to encourage promising young scientists to pursue careers in cancer research.
A study suggests that combining NKTR-214 with adoptive cell therapy may produce a stronger immune response against advanced melanoma, increasing the number of anti-tumor immune cells and their lifespan. This approach could be effective for more patients with advanced solid tumors.
Researchers at Tokyo University of Science discovered a novel anti-cancer strategy targeting tumor-associated macrophages (TAMs) by regulating FROUNT protein. Disulfiram, an alcoholism treatment, was found to inhibit cancer cell growth and suppress TAM movement in animal experiments.
Researchers at the Francis Crick Institute have discovered the mechanism behind HIV's resistance to a widely-prescribed group of drugs. By exploring the structure of integrase using cryo-electron microscopy, they found that the virus can weaken the bond between the drug and its target, enabling its key enzyme to work again.